Across TCGA pan-cancer cohorts, LINC02249 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LINC02249’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02249 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02249 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.
BRCA, LUSC, and PAAD are the cancer types where LINC02249 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02249 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.